Skip to main content
SpringerLink
Log in

Lyse

  • Chapter
Book cover HerzAkutMedizin

  • 863 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu Kapitel 2.4

  1. Abbottsmith CW, Topol EJ, George BS et al (1990) Fate of patients with acute myocardial infarction with patency of the infarct-related artery achieved with successful thrombolysis versus rescue angioplasty. J Am Coll Cardiol 16:770–778

    Article  PubMed  CAS  Google Scholar 

  2. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS, for the DANAMI-2 Investigators (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742

    Article  PubMed  Google Scholar 

  3. Antman EM (1994) Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 90:1624–1630

    PubMed  CAS  Google Scholar 

  4. Antman EM, Giugliano RP, Gibson CM et al (1999) Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI-14 Investigators. Circulation 99:2720–2732

    PubMed  CAS  Google Scholar 

  5. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Gullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines www.acc.org/clinical/guidelines/stemi/index.pdf

    Google Scholar 

  6. Antoniucci D, Valenti R, Migliorini A et al (2002) Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 89:1248–1252

    Article  PubMed  Google Scholar 

  7. ASSENT-2 (Assessment of the safety and eficacy of a new thrombolytic) Investigators single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction (1999) The ASSENT-2 double-blind randomised trial. Lancet 354:716–722

    Google Scholar 

  8. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL (1990) Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66:1412–1417

    Article  PubMed  CAS  Google Scholar 

  9. Bode C, Smalling RW, Sen S et al (1993) Recombinant plasminogen activator angiographic phase Il international dose finding study (RAPID): patency analysis and mortality endpoints. Circulation 88:1–292 (abstr 1562)

    Google Scholar 

  10. Bode C, Smalling RW, Berg G et al, for the RAPID II Investigators (1996) Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase in patients with acute myocardial infarction. Circulation 94:891–898

    PubMed  CAS  Google Scholar 

  11. Boersma E, Maas ACP, Deckers JW et al (1996) Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348:771–775

    Article  PubMed  CAS  Google Scholar 

  12. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G et al (2002) On behalf of the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) study group. Lancet 360:825–829

    Article  PubMed  Google Scholar 

  13. Brener SJ, Zeymer U, Adgey AA et al (2002) Eptifibatide and low-dose tissue plasminogen activator in acute MI: the INTRO AMI trial. J Am Coll Cardiol 39:377–386

    Article  PubMed  CAS  Google Scholar 

  14. Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Harrelson-Woodlief L, Wall TC, Phillips HR, Abbottsmith CW, Candela RJ, Flanagan WH, Sasahara AA, Mantell SJ, Lee KL (1991) Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of Thrombolysis and Angioplasty in Myocardial Infarction phase 5 randomized trial (TAMI-5). Circulation 83:1543–1556

    PubMed  CAS  Google Scholar 

  15. Califf R, O’Neill W, Stack R et al (1988) Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 108:658–662

    PubMed  CAS  Google Scholar 

  16. entfällt

    Google Scholar 

  17. Califf RM, Fortin DF, Tenaglia AN, Sane DC (1992) Clinical risks of thrombolytic therapy. Am J Cardiol 69:12A–20A

    Article  PubMed  CAS  Google Scholar 

  18. Cannon CP, Antman EM, Walls R, Braunwald E (1994) Time as an adjunctive agent to thrombolytic therapy. Journal of Thrombosis and Thrombolysis 1:27–34

    Article  PubMed  Google Scholar 

  19. Cannon CP, McCabe CH, Gibson CM et al for the TIMI 10A Investigators (1997) TNK-tissue plasminogen activator in acute myocardial infarction. Circulation 95:351–356

    PubMed  CAS  Google Scholar 

  20. Cannon CP, Gibson CM, McCabe CH et al (1998) TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results fo the TMI 10B trial: Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 98:2805–2814

    PubMed  CAS  Google Scholar 

  21. Carney RJ, Murphy GA, Brandt TR, Daley PJ, Pickering E, White HJ, McDonough TJ, Vermilya SK, Teichman SL for the RAAMI Study Investigators (1992) Randomised angiographic trial of recombinant tissue-type plasminogen activator (Alteplase) in myocardial infarction. J Am Coll Cardiol 20:17–23

    PubMed  CAS  Google Scholar 

  22. Clemmensen P, Ohmann E, Sevila D et al (1990) Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. Am J Cardiol 66:1407–1411

    Article  PubMed  CAS  Google Scholar 

  23. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M (1991) A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 151:333–337

    Article  PubMed  CAS  Google Scholar 

  24. Davies GJ, Chierchia S, Maseri A (1984) Prevention of myocardial infarction by very early treatment with intracoronary streptokinase: some clinical observations. N Engl J Med 311:1488–1492

    Article  PubMed  CAS  Google Scholar 

  25. de Bono DP, on behalf of the European Cooperative Study Group (ECSG-6) (1992) Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group (ECSG-6). Br Heart J 67:122–128

    PubMed  Google Scholar 

  26. de Lemos JA, Antman EM, McCabe CH et al (2000) ST-segment resolution and infarct related artery patency and flow after thrombolytic therapy. Am J Cardiol 85:299–304

    Article  PubMed  Google Scholar 

  27. den Heijer P, Vermeer F, Ambrosioni E et al for the InTIME Investigators (1998) Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. Circulation 98:2117–2125

    Google Scholar 

  28. DeWood MA, Spores J, Notkse R, Mouser LT, Burroughs R et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902

    Article  PubMed  CAS  Google Scholar 

  29. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin (2001) The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358:605–613

    Article  PubMed  Google Scholar 

  30. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group (1992) Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 342:767–772

    Google Scholar 

  31. EMIP. The European Myocardial Infarction Project Group (EMIP) (1993) Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 329:383–389

    Article  Google Scholar 

  32. Falk E, Schah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671

    PubMed  CAS  Google Scholar 

  33. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A et al (2003) GRAICA-2 Investigators. Primary optimal PCI versus facilitated intervention (tenecteplase plus stenting) in patients with ST-elevated acute myocardial infarction: the GRACIA-2 randomized trial [abstract]. Circulation 108(Suppl):IV468

    Google Scholar 

  34. Fennerty AG, Levine MN, Hirsh J (1989) Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboemoblism. Chest 95(Suppl):88S–97S

    PubMed  CAS  Google Scholar 

  35. FTT. ‚Fibrinolytic Therapy Trialists ‘Collaborative Group (1994) Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343:311–322

    Google Scholar 

  36. Gibson CM, Cannon CP, Piana RN et al (1993) Consequences of TIMI grade 2 vs 3 flow at 90 minutes following thrombolysis. J Am Coll Cardiol 21(Suppl A):348A

    Google Scholar 

  37. GISSI-I (1986) Gruppo Italiano per lo Studio della Streptochinasi nell’lnfarto Miocardico. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397–402

    Google Scholar 

  38. GISSI-2 (1990) A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio Delia Sopravvivenza nell’lnfarto Miocardico. Lancet 336:65–71

    Google Scholar 

  39. Giugliano RP, Braunwald E (2003) Selectin the best reperfusion strategy in ST-elevation myocardial infarction: it’s all a matter of time. Circulation 108:2828–2830

    Article  PubMed  Google Scholar 

  40. Gore JM, Sloan M, Price TR, Randall AMY, Bovill E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML, and the TIMI Investigators (1991) Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infaction and thrombolytic therapy in the thrombolysis in myocardial infarction study, thrombolysis in myocardial infarction, phase II, pilot and clinical trial. Circulation 83:448–459

    PubMed  CAS  Google Scholar 

  41. Granger BC, Califf RM, Topol EJ (1992) Thrombolytic therapy for acute myocardial infarction. A review. Drugs 44:293–325

    PubMed  CAS  Google Scholar 

  42. Grines CL, Topol EJ, Bates ER, Juni JE, Walton JA, O’Neill WW (1988) Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. Am Heart J 115:1–7

    Article  PubMed  CAS  Google Scholar 

  43. GUSTO-I (1993) The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial. N Engl J Med 329:673–682

    Google Scholar 

  44. GUSTO-I (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 329:1615–1622

    Google Scholar 

  45. GUSTO IIa (1994) The GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631–1637

    Google Scholar 

  46. Hamm CW (2004) Leitlinien: Akutes Koronarsyndrom (ACS), Teil-2: Akutes Koronarsyndrom mit ST-Hebung. Zeitschrift für Kardiologie 93:324–341

    Article  PubMed  CAS  Google Scholar 

  47. HERO-2 Trial Investigators (2001) Thrombin-specific antiocoagulation with bivalirduin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 Trial. Lancet 358:18655–18663

    Google Scholar 

  48. Herrick JB (1912) Clinical features of sudden obstruction of the coronary arteries. Journal of the American Medical Association 59:2015–2019

    Google Scholar 

  49. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman B, Ross AM (1990) A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323:1433–1437

    Article  PubMed  CAS  Google Scholar 

  50. INJECT (1995) International Joint Efficacy Comparison of Thrombolytics: randomised double-blind comparison to reteplase doublebolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 346:329–336

    Article  Google Scholar 

  51. International Study Group (1990) In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 336:71–75

    Article  Google Scholar 

  52. ISIS-2 (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet ii:349–360

    Google Scholar 

  53. ISIS-3 (1992) A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 339:753–770

    Google Scholar 

  54. Ito H, Tomooka T, Sakai N et al (1992) Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 85:1699–1705

    PubMed  CAS  Google Scholar 

  55. Kastrati A, Mehilli J, Schlotterbeck K et al (2004) Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 291:947–954

    Article  PubMed  CAS  Google Scholar 

  56. Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13–20

    Article  PubMed  Google Scholar 

  57. Klootwijk P, Langer A, Meij S et al (1996) Non-invasive predictin of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-1 trial. Eur Heart J 17:689–698

    PubMed  CAS  Google Scholar 

  58. Komrad MS, Coffey CE, Coffey KS, McKinnis R, Massey EW, Califf RM (1984) Myocardial infarction and stroke. Neurology 34:1403–1409

    PubMed  CAS  Google Scholar 

  59. LATE Study Group (1993) Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 h after onset of acute myocardial infarction. Lancet 342:759–766

    Article  Google Scholar 

  60. Lincoff AM, Ellis SG, Galeana A et al (1992) Is a coronary artery with TIMI grade 2 flow „patent“? Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trial. Circulation 86(Suppl 1):1–268

    Google Scholar 

  61. Lincoff AM, Topoi EJ (1993) Trickle down thrombolysis. J Am Coll Cardiol 21:1396–1398

    PubMed  CAS  Google Scholar 

  62. Lincoff AM, Topoi EJ (1993) Illusion of reperfusion. Circulation 87:1792–1805

    Google Scholar 

  63. Lincoff AM, Califf RM, Van de Werf F et al (2002) Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 288:2130–2135

    Article  PubMed  CAS  Google Scholar 

  64. Maggioni AP, Franzosi MG, Farina ML, Santoro E, Celani MG, Ricci S, Tognoni G, on behalf of the Gruppo Italiano per lo Studio deila Streptochinasi nell’lnfarto Miocardico (GISSI) (1991) Cerebrovascular events after myocardial infarction: analysis of the GISSI trial. Br Med J 302:1428–1431

    Article  CAS  Google Scholar 

  65. Montalescot G, Barragan P, Wittenberg O et al (2001) Platelet GP IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895–1903

    Article  PubMed  CAS  Google Scholar 

  66. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ (2000) Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 283:2686–2692

    Article  PubMed  CAS  Google Scholar 

  67. Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevantion myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation. An intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy. Circulation 102:2031–2037

    PubMed  CAS  Google Scholar 

  68. National Heart Attack Alert Program Coordinating Committee — 60 Minutes to Treatment Working Group (1994). Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 23:311–329

    Google Scholar 

  69. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U (1989) Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 14:1566–1569

    Article  PubMed  CAS  Google Scholar 

  70. Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Foryeki F, Wirtzfeld A, Mäurer W, Limbourg P, Merx W, Harten K (1992) Improved thrombolysis in acute myocardial infarction with frontloaded administration of alteplase: results of the rt-PA-APSAC Patency Study (TAPS). J Am Col Cardiol 19:885–891

    CAS  Google Scholar 

  71. Neuhaus KL, von Essen R, Vogt A et al (1994) Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study (GRECO). J Am Col Cardiol 24:55–60

    CAS  Google Scholar 

  72. Neuhaus KL, Essen RV, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T (1994) Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 90:1638–1642

    PubMed  CAS  Google Scholar 

  73. Newby LK, Rutsch WR, Califf RM, Limoons ML, Aylward PE, Armstrong PW, Woodlief LH, Lee KL, Topoi EJ, Van de Werf F, for the GUSTO-I Investigators (1995) The importance of time from symptom onset to treatment in the outcome of patients treated with thrombolytic therapy

    Google Scholar 

  74. Nordt TK, Bode C (2001) Thrombolysetherapie des akuten Herzinfarktes. Internist 42:659–664

    Article  PubMed  CAS  Google Scholar 

  75. Ohman EM, Califf RM (1991) Thrombolytic therapy: overview of clinical trials. In: Gersh BJ, Rahimtoola SH (eds) Acute myocardial infarction. New York, NY, Elsevier, pp 308–332

    Google Scholar 

  76. Ohman EM, Kleiman NS, Gacioch G et al (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in AMI: results of IMPACT-AMI. Circulation 95:846–854

    PubMed  CAS  Google Scholar 

  77. PRIMI Trial Study Group (1989) Randomised double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1:863–868

    Google Scholar 

  78. Rentrop KP, Blanke H, Karsch KR, Kreuzer H (1979) Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction: comparison with conventionally treated patients. Clinical Cardiology 2:92–105

    PubMed  CAS  Google Scholar 

  79. Ross A, Lundergan C, Rohrbeck S, Boyle D (1998) Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. J Am Coll Cardiol 31:1511–1517

    Article  PubMed  CAS  Google Scholar 

  80. Ross AM, Coyne KS, Reiner JS et al (1999) PACT Investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 34:1954–1962

    Article  PubMed  CAS  Google Scholar 

  81. Rutsch W, Pfisterer M, Weaver WD, Granger BC, Lee KL, Ross A, for the GUSTO-I Trial Investigators (1993) Earlier time to treatment is associated with lower mortality and greater benefit of accelerated t-PA. Abstract at the American Heart Association, 66th Scientific Sessions, Atlanta, November 8–11

    Google Scholar 

  82. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS (1989) Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 111:1010–1022

    PubMed  CAS  Google Scholar 

  83. Schröder R, Biamino G, von Leitner ERV, Linderer T, Brüggemann T, Heitz J, Vöhringer HF, Wegscheider K (1983) Intravenous short term infusion of streptokinase in acute myocardial infarction. Circulation 67:536–548

    PubMed  Google Scholar 

  84. Schröder R, Dissmann R, Bruggemann T et al (1994) Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 24:384–391

    PubMed  Google Scholar 

  85. Schröder R, Wegscheider K, Schröder K, Dissmann R, Meyer-Sabellek W, for the INJECT Trial Group (1995) Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 26:1657–1664

    Article  PubMed  Google Scholar 

  86. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators (1995) Link between the angiographic substudy and mortality outcomes in at large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 91:1923–1928

    PubMed  CAS  Google Scholar 

  87. Simoons, ML, Betriu A, Col J, von Essen R, Lubsen J, Michel PL, Rutsch W, Schmidt W, Thery C, Vahanian A, Willems GM, Arnold AER, DeBono DP, Dougherty PC, Lambertz H, Meier B, Raynaud P, Sanz GA, Uebis R, Van de Werf F, Wood D, Verstraete M (1988) for the European Cooperative Study Group for Recombinant Tissue-type Plasmi-nogen Activator (rt-PA) (ECSG-5): Thrombolysis with tissue plasminogen activator in acute myocardial infartion: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 8579:197–202

    Article  Google Scholar 

  88. Sinnaeve P, Alexander J, Belmans A et al (2003) One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase und front-loaded alteplase in 16949 patients with ST-elevation acute myocardial infarction. Am Heart J 146:27–32

    Article  PubMed  CAS  Google Scholar 

  89. Smalling RW, Schumacher R, Morris D, Harder K, Fuentes F, Valentine RP, Battey LL, Merhige M, Pitts DE, Lieberman HA, Nishikawa A, Adyanthaya A, Hophins A, Grossbard E (1990) Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol 15:915–921

    PubMed  CAS  Google Scholar 

  90. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, Leizorovicz A, Touboul P, for the Comparison of Angioplasty and Prehospital Thrombolysis in acute Myocardial infarction (CAPTIM) Investigators (2003) Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty data from the CAP-TIM Randomized Clinical Trial. Circulation 108:2851–2856

    Article  PubMed  Google Scholar 

  91. Stone GW, Grines CL, Cox DA et al (2002) Controlled Abciximab and Device Investigators to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957–966

    Article  PubMed  CAS  Google Scholar 

  92. TEAM-2, Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL (1992) Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a most patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 19:1–10

    PubMed  CAS  Google Scholar 

  93. Topol EJ (1989) Thrombolytic intervention. In: Topoi EJ (ed) Textbook of Interventional Cardiology, Philadelphia, PA, Saunders, pp 76–120

    Google Scholar 

  94. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM, and the TAMI Study Group (1989) A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79:281–286

    PubMed  CAS  Google Scholar 

  95. Topol EJ (1993) Validation of the early open infarct vessel hypothesis. Am J Cardiol 72:40G–45G

    Article  PubMed  CAS  Google Scholar 

  96. Topol EJ, Ohman EM, for the SPEED Investigators (2001) Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 101:2788–2794

    Google Scholar 

  97. Topol EJ (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357:1905–1914

    Article  PubMed  CAS  Google Scholar 

  98. The Global Utilization of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators (1996) A comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775–782

    Article  Google Scholar 

  99. The GUSTO III Investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118–1123

    Article  Google Scholar 

  100. The Joint European Society of Cardiology/ American College of Cardiology Comittee (2000) Myocardial infarction redefined — a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. JACC 36:959–969

    Google Scholar 

  101. The Joint International Society and Federation of Cardiology/ World Health Organisation Task FORCE (1997) Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on standardization of clinical nomenclature. Circulation 59:607–609

    Google Scholar 

  102. Van de Werf F, Cannon CP, Luyten A et al (1999) Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: ASSENT-1 trial: the ASSENT-1 Investigators. Am Heart J 137:786–791

    Article  PubMed  Google Scholar 

  103. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL (1993) Impact of early perfusion status of the infarct related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 21:1391–1395

    Article  PubMed  CAS  Google Scholar 

  104. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AAJ, Arntz HR, Bogaerts K, Danays T, Lindahl B, Mäkijärvi M, Verheugt F, Van de Werf F (2003) Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin Enoxaparin or unfractionated heparin in the prehospital setting [ASSENT-3 Plus]. Circulation 108:135–142

    Article  PubMed  CAS  Google Scholar 

  105. Waller BF (1988) The pathology of acute myocardial infarction: definition, location, pathogenesis, effects of reperfusion, complications, and sequelae. Cardiology Clinics 6:1–28

    PubMed  CAS  Google Scholar 

  106. Ward JW, Holmberg SD, Allen JR, Cohn DL, Critchley SE, Kleinman SH, Lenes BA, Ravenholt O, Davis JR, Quinn MG, Jaffe HW (1988) Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negativ for HIV antibody. N Engl J Med 318:473–478

    Article  PubMed  CAS  Google Scholar 

  107. Weaver WD, Cerqueira M, Hallstrom AP et al for the Myocardial Infarction Triage and Intervention Project Group (1993) Prehospital-initiated vs hospital-initiated thrombolytic therapy. Myocardial Infarction Triage and Intervention Trial (MITI). JAMA 270:1211–1216

    Article  PubMed  CAS  Google Scholar 

  108. Widimsky P, Budesinsky T, Vorac D, Groch L et al (2003) Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial — PRAGUE-2. Europ Heart J 24:94–104

    Article  CAS  Google Scholar 

  109. Willerson JT, Campbell WB, Winniford MD, Schmitz J, Apprill P, Firth BG, Ashton J, Smitheraman T, Bush L, Buja LM (1984) Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. Am J Cardiol 54:1349–1354

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik, Campus Charité Mitte, Charité Universitätsmedizin Berlin, Schumannstr. 20/21, 10117, Berlin

    Prof. Dr. W. Rutsch

Authors
  1. Prof. Dr. W. Rutsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Herz- und Thoraxchirurgie, Universitätsspital Basel, Spitalstr. 21, 4031, Basel, Schweiz

    H. -R. Zerkowski

  2. Medizinische Klinik mit Schwerpunkt Kardiologie, Angiologie und Pneumologie, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Schumannstr. 20/21, 10117, Berlin

    G. Baumann

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Rutsch, W. (2006). Lyse. In: Zerkowski, H.R., Baumann, G. (eds) HerzAkutMedizin. Steinkopff. https://doi.org/10.1007/3-7985-1630-8_17

Download citation

  • DOI: https://doi.org/10.1007/3-7985-1630-8_17

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1505-5

  • Online ISBN: 978-3-7985-1630-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation